Table 2.
Frequence and outcome of HCC in patients with NAFLD.
| Author/year | HCC n/% | HCC risk: HR or OR (95%CI) | Type of analysis | HCC DFS: HR (95%CI) | Type of analysis | Cancer mortality HR (95%CI) | Type of analysis | HCC OS: HR (95%CI) | Type of an alysis | NOS score |
|---|---|---|---|---|---|---|---|---|---|---|
| Aigelsreiter/2016 | - | - | - | 1.07 (0.67-1.69) | UVA | - | - | 1.14 (0.69-1.89) | UVA | 8 |
| Alexander/2019 | 176/0.1 | 3.76 (1.96-7.20)° | MVA | - | - | - | - | - | - | 6 |
| Alvarez/2020 | - | - | - | - | - | 1.13 (0.91-1.39) | MVA | 1.2 (0.8-1.34) | MVA | 9 |
| Amarapurkar/2008 | 54/9.2 | - | - | - | - | - | - | - | - | 5 |
| Ampuera/2015 | 7/20.6 | - | - | - | - | - | - | - | - | 5 |
| Arase/2012 | 10/6 | - | - | - | - | - | - | - | - | 8 |
| Asahina/2013 | - | 2.29 (1.49-3.50)^ | MVA | - | - | - | - | - | - | 8 |
| Ascha/2010 | 25/12.8 | - | - | - | - | - | - | - | - | 7 |
| Asfari/2020 | 10947/0.5 | 1.6 (1.4-1.9)° | MVA | - | - | - | - | - | - | 6 |
| Bengtsson/2019 | 225/14.4 | - | - | - | - | - | - | - | - | 6 |
| Best/2020 | 29/7.1 | - | - | - | - | - | - | - | - | 8 |
| Beste/2015 | 1029/- | - | - | - | - | - | - | - | - | 9 |
| Bhala/2011 | 6/2.4 | - | - | - | - | - | - | - | - | 8 |
| Carr/2081 | 16/- | - | - | - | - | - | - | - | - | 5 |
| Chan/2017 | 11/4.1 | 6.58 (0.9-46.8)* 3.2 (0.8-12.3)° | UVA | - | - | - | - | - | - | 9 |
| Chen/2014 | 50/- | 0.66 (0.44–0.99) | MVA | - | - | - | - | - | - | 5 |
| Cho/2011 | 54/- | - | - | - | - | - | - | - | - | 5 |
| Choi/2020 | 16/8.6 | 3.06 (1.91-4.91)° | UVA | - | - | - | - | - | - | 9 |
| Chuma/2008 | 35/33.7 | 1.5 (0.66–3.4)^ | MVA | - | - | - | - | - | - | 9 |
| Cotrim/2011 | 3/0.2 | - | - | - | - | - | - | - | - | 5 |
| D'Ambrosio/2018 | 5/- | 0.99 (0.09-10.89) | UVA | - | - | - | - | - | - | 9 |
| Dal Bello/2010 | 207/- | - | - | 1.11 (0.86-1.42) | UVA | - | - | - | - | 6 |
| Doycheva/2019 | 1925/- | 0.55 (0.52-0.59) | MVA | - | - | - | - | - | - | 5 |
| Dugum/2015 | 838/- | - | - | - | - | - | - | - | - | 7 |
| Dunn/2013 | 2/1 | 0.42 [0.10, 1.76] | UVA | - | - | - | - | - | - | 5 |
| Ekstedt/2015 | - | - | - | - | - | 6.55 (2.14-20) | UVA | 1.24 (1.04-1.59) | UVA | 9 |
| El-derany/2020 | 55/- | - | - | - | - | - | - | - | - | 5 |
| Ertle/2011 | 36/- | - | - | - | - | - | - | - | - | 5 |
| Grimaudo/2020 | 13/2.7 | - | - | - | - | - | - | - | - | 8 |
| Hamoir/2021 | 3/18.7 | 14.93 (1.08-206.39) | MVA | - | - | - | - | - | - | 6 |
| Hashimoto/2009 | 34/8.9 | 0.28 (0.18-0.45) | UVA | - | - | - | - | - | - | 6 |
| Hayashi/2016 | 544/- | - | - | 1.17 (0.90-1.53) | MVA | - | - | 1.63 (1.09-2.52) | MVA | 7 |
| Hernandez-Alejandro/2012 | 17/- | - | - | - | - | - | - | - | - | 5 |
| Hester/2019 | 2820/- | - | - | - | - | - | - | 1.44 (1.01-2.07) | MVA | 8 |
| Hsiang/2014 | - | 4.78 (1.05-21.79) | MVA | - | - | 1.11 (1.01-1-13) | MVA | - | - | 6 |
| Huang/2017 | - | 1.33 (0.32-5.53) | MVA | - | - | - | - | - | - | 5 |
| Huang/2020 | 226/2 | 1.69 (1.43-2) | MVA | - | - | 0.67 (0.48-0.95) | MVA | - | - | 7 |
| Hui/2003 | 0/0 | - | - | - | - | - | - | - | - | 7 |
| Ioannou/2019 | 690/54 | - | - | - | - | - | - | - | - | 5 |
| Jain/2012 | 8/17 | - | - | - | - | - | - | - | - | |
| Ji/2021 | 54/4.3 | 2.4 (1.3-4-2) | MVA | - | - | - | - | - | - | 6 |
| Kai/2017 | 83/100 | - | - | 1.22 (0.51-2.89) | UVA | - | - | 1.07 (0.42-2.73) | UVA | 6 |
| Kanwal/2018 | 367/0.12 | 7.62 (5.76-10.09) | MVA | - | - | - | - | - | - | 9 |
| Kaplan/2019 | - | 0.94 (0.90-0.99) | MVA | - | - | - | - | - | - | 6 |
| Kawamura/2011 | 16/0.25 | - | - | - | - | - | - | - | - | 5 |
| Kim/2018 | 13/8721 | 16.73 (2.09-133.85) | MVA | - | - | - | - | - | - | 6 |
| Kodama/2013 | 16/- | - | - | - | - | - | - | - | - | 7 |
| Kumar/2005 | 25/- | 4.1 (0.4-39)* | MVA | - | - | - | - | - | - | 8 |
| Kurosaki/2010 | 68/- | 3.04 (1.82-5.06) | MVA | - | - | - | - | - | - | 7 |
| Lee/2016 | - | 0.57 (0.07-4.74) | UVA | - | - | - | - | - | - | 7 |
| Li/2021 | 40/3.74 | 0.72 (0.41-1.30) | MVA | - | - | - | - | - | - | 9 |
| Lim/2020 | 27/289 | 2.44 (0.97-6.1) | MVA | - | - | - | - | - | - | 9 |
| Lin/2021 | 369/- | - | - | 0.9 (0.72-0.13) | UVA | 0.74 (0.51-1.07) | UVA | - | - | 8 |
| Malik/2009 | 17/17.3 | - | - | - | - | - | - | - | - | 7 |
| Marot/2017 | 12/15 | 2.56 (1.31-5.00) | MVA | - | - | - | - | - | - | 5 |
| Mittal/2015 | 120/- | - | - | - | - | - | - | 0.8 (0.6-1.0) | MVA | 5 |
| Nakajima/2011 | 14/15.2 | 0.22 (0.09-0.61) | UVA | - | - | - | - | - | - | 5 |
| Nirei/2017 | 12/7 | 4.92 (0.13-186)* | MVA | - | - | - | - | - | - | 5 |
| Nkontchou/2011 | 96/28 | 1.32 (0.73-2.39)* | - | - | - | - | - | - | - | 7 |
| Ogawa/2020 | 16/0.5 | 1.56 (0.39-6.24)* | UVA | - | - | - | - | - | - | 7 |
| Ohata/2003 | - | 2.81 (1.24-6.37)^ | MVA | - | - | - | - | - | - | 8 |
| Paradis/2009 | 60/- | - | - | - | - | - | - | - | - | 5 |
| Pekow/2006 | 32/- | 6.39 (1.04-39.3)* | MVA | - | - | - | - | - | - | 5 |
| Peleg/2019 | 14/5.8 | 4.35 (1.69-11.2) | MVA | - | - | - | - | - | - | 8 |
| Phan/2019 | 3/- | - | - | - | - | - | - | - | - | 5 |
| Pinyopornpanish/2021 | 346/- | - | - | - | - | - | - | 1.08 (0.98-1.28) | MVA | 6 |
| Reddy/2012 | 52/- | - | - | - | - | - | - | 0.50 (0.29-0.88) | MVA | 6 |
| Sadler/2017 | 60/- | - | - | 0.93 (0.45-1.92) | UVA | - | - | - | - | 8 |
| Safcak/2021 | 54/- | - | - | - | - | - | - | - | - | 5 |
| Sanyal/2010 | 2578/58.5 | - | - | - | - | - | - | - | - | 5 |
| Schutte/2014 | 43/- | - | - | - | - | - | - | 0.57 (0.24-1.34) | UVA | 5 |
| Sharma/2018 | 8/3.5 | 2.12 (0.91-4.92) | MVA | - | - | - | - | - | - | 5 |
| Shibahara/2014 | 106/- | - | - | 0.87 (0.62-1.23)^0.83 (0.55-1.25)° | UVA | - | - | 0.80 (0.41-1.56)^0.75 (0.34-1.64)° | UVA | 5 |
| Shimomura/2017 | - | - | - | - | - | - | - | - | - | 6 |
| Shingina/2019 | 2181/13 | - | - | - | - | - | - | - | - | 6 |
| Simon/2021 | 186/- | - | - | - | - | - | - | - | - | 6 |
| Su/2015 | 74/- | - | MVA | - | - | - | - | - | - | 7 |
| Takahashi/2011 | 6/46.2 | 5.7 (1.9-17.1) | MVA | - | - | - | - | - | - | 7 |
| Takuma/2007 | 25/- | - | - | 3.31 (1.49-7.41) | MVA | - | - | - | - | 7 |
| Tanaka/2013 | 6/16.7 | - | - | - | - | - | - | - | - | 5 |
| Tateishi/2015 | 596/- | - | - | - | - | - | - | - | - | 6 |
| Thuluvath/2018 | 2166/19 | - | - | - | - | - | - | - | - | 5 |
| Tokushige/2010 | 34/- | - | - | - | - | - | - | - | - | 7 |
| Tokushige/2013 | 292/- | - | - | - | - | - | - | - | - | 5 |
| Van Meer/2015 | 176/- | - | - | - | - | - | - | - | - | 6 |
| Van Meer/2016 | 181/- | 2.59 (1.58-4.26) | MVA | - | - | - | - | - | - | 6 |
| Viganò/2015 | 96/- | - | - | 0.55 (0.36-0.85) | MVA | - | - | 0.53 (031-0.91) | MVA | 7 |
| Wakai/2011 | 17/- | 0.45 (0.17-1.17) | MVA | - | - | - | - | - | - | 8 |
| Walker/2016 | 204/- | - | - | - | - | - | - | - | - | 5 |
| Wang/2021 | 39/0.2 | 1.07 (0.73-1.58) | UVA | - | - | - | - | - | - | 5 |
| Wild/2018 | 19/- | 19.3 (11.8-31.4) | - | - | - | 6.16 (3.02-12.6) | MVA | - | - | 7 |
| Wong/2019 | 138/- | 0.78 (0.20-3.03) | UVA | - | - | - | - | - | - | 5 |
| Yatsuji/2008 | 7/10 | - | - | - | - | - | - | - | - | 5 |
| Wu/2011 | 355/- | - | - | 0.92 (0.71-1.19) | MVA | - | - | 0.81 (0.61-1.08) | MVA | 6 |
| Wu/2018 | 113/- | - | - | - | - | - | - | 2.16 (1.21-3.84) | - | 5 |
| Yang/2016 | - | 1.10 (0.40-3.02) | MVA | - | - | - | - | - | - | 6 |
| Yen/2017 | 140/14.36 | 1.37 (0.88-2.13) | MVA | - | - | - | - | - | - | 8 |
| Yoon/2020 | 196/50 | - | - | 1.02 (0.73-1.43) | MVA | - | - | 0.94 (0.51-1.73) | MVA | 8 |
| Younossi/2019 | 2690/- | - | - | - | - | 4.17 (3.81-4.56) | MVA | 0.76 (0.65-0.89) | MVA | 5 |
| Yu/2008 | - | 0.24 (0.14-0.41) | MVA | - | - | - | - | - | - | 9 |
| Zhang/2016 | 6/1.38 | 11.46 (1.34-98.01) | MVA | - | - | - | - | - | - | 5 |
| Zheng/2017 | 141/- | - | - | 0.70 (0.50-0.98) | MVA | - | - | 0.68 (0.49-0.94) | MVA | 6 |
HCC, hepatocellular carcinoma; HR, hazard ratio; OR, odds ratio; CI, confidence interval; DFS, disease-free survival; OS, overall survival; UVA, univariate analysis; MVA, multivariate analysis; *, grade 2-3 vs 0; °, steatohepatitis; ^, steatosis grade 1-3 vs 0, **, composite outcome of cancer incidence and mortality.